Prognostic factors in mucoepidermoid carcinoma of the salivary glands

Cancer

Volumn 118, Issue 16, 2012, Pages 3928-3936

  McHugh, Catherine H ^a,b   Roberts, Dianna B ^b   El Naggar, Adel K ^b   Hanna, Ehab Y ^b   Garden, Adam S ^b   Kies, Merrill S ^b   Weber, Randal S ^b   Kupferman, Michael E ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

mucoepidermoid carcinoma; parotid gland; salivary gland carcinoma; submandibular gland; treatment intensification

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOSQUAMOUS CARCINOMA; ADULT; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SALIVARY GLAND CARCINOMA; TERTIARY HEALTH CARE;

CARCINOMA, MUCOEPIDERMOID; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS;

EID: 84864673597     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26697     Document Type: Review

References (27)

1. McHugh JB, Visscher DW, Barnes EL,. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009; 133: 1763-1774.
2. Pinkston JA, Cole P,. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999; 120: 834-840.
3. Luna MA,. Salivary mucoepidermoid carcinoma: Revisited. Adv Anat Pathol. 2006; 13: 293-307.
4. Tirado Y, Williams HD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK,. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer. 2007; 46: 708-715.
5. Cheuk W, Chan JK,. Advances in salivary gland pathology. Histopathology. 2007; 51: 1-20.
6. Spiro RH, Huvos AG, Berk R, Strong EW,. Mucoepidermoid carcinoma of salivary gland origin: a clinicopathologic study of 367 cases. Am J Surg. 1978; 136: 461-468.
7. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001; 25: 835-845.
8. Hicks MJ, el-Naggar AK, Byers RM, Flaitz CM, Luna MA, Batsakis JG,. Prognostic factors in mucoepidermoid carcinomas of major salivary glands: a clinicopathologic and flow cytometric study. Eur J Cancer B Oral Oncol. 1994; 30B: 329-334.
9. Goode RK, Auclair PL, Ellis GL,. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998; 82: 1217-1224.
10. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006; 28: 197-204.
11. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
12. Loh KS, Barker E, Bruch G, et al. Prognostic factors in malignancy of the minor salivary glands. Head Neck. 2009; 31: 58-63.
13. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AH, Strong EW,. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg. 1991; 162: 330-336.
14. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA,. Stage as major long-term outcome predictor in minor salivary gland carcinoma. Cancer. 2000; 89: 1195-1204.
15. Terhaard CH, van der Schroeff MP, van Schie K, et al. The prognostic role of comorbidity in salivary gland carcinoma. Cancer. 2008; 113: 1572-1579.
16. Nance MA, Seethala RR, Wang Y, et al. Treatment and survival outcomes based on histological grading in patients with head and neck mucoepidermoid carcinoma. Cancer. 2008; 113: 2082-2089.
17. Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS,. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007; 133: 546-550.
18. Lin AC, Bhattacharyya N,. The utility of fine needle aspiration in parotid malignancy. Otolaryngol Head Neck Surg. 2007; 136: 793-798.
19. Cheung RL, Russell AC, Freeman J,. Does routine preoperative imaging of parotid tumors affect surgical management decision making? J Otolaryngol. 2008; 37: 430-434.
20. Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987; 5: 951-955.
21. Laurie SA, Licitra L,. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24: 2673-2678.
22. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced of metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003; 39: 724-727.
23. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25: 3978-3984.
24. Cooper JS, Pajak TF, Forastiere AA, et al. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
25. Bernier J, Domenge C, Ozsahin M, et al. European Organisation for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
26. Katori H, Tsukuda M,. Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma. Acta Otolaryngol. 2006; 126: 1309-1314.
27. Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009; 135: 687-692.